Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS' (Centers for Medicare & Medicaid Services) OPT (ocular photodynamic therapy) with verteporfin decision cheers QLT/Novartis

This article was originally published in Clinica

Executive Summary

The Centers for Medicare & Medicaid Services (CMS) has finally settled on a coverage policy for ocular photodynamic therapy (OPT) with verteporfin, the only known treatment of the eye condition known as age-related macular degeneration (AMD). The agency announced on January 29 that it is prepared to cover the product for patients with two forms of "wet" AMD caused by the development of abnormally leaky blood vessels known as choroidal neovascularisation (CNV).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT057188

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel